Ildong 
Welcome,         Profile    Billing    Logout  
 14 Products   60 Diseases  14 Products   28 Trials   2767 News 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belviq (lorcaserin) / Eisai
NCT02400359: Lorcaserin in Obesity: Identification of CNS Targets Using FMRI

Active, not recruiting
4
40
US
Lorcaserin HCl, Belviq, Placebo
Beth Israel Deaconess Medical Center
Obesity, Weight Loss
03/26
03/26
MOMENTUM 1, NCT04572243: A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Terminated
3
28
Canada, US
Placebo, Lorcaserin, E2023
Eisai Inc.
Epilepsies, Myoclonic
08/24
08/24
NCT03266939: Rebalancing the Serotonergic System in Cocaine Dependence

Active, not recruiting
1
10
US
Lorcaserin, Placebo Oral Tablet
Mclean Hospital
Cocaine Dependence
12/21
12/21
NCT04457687: Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Available
N/A
Canada, US
Lorcaserin, E2023
Eisai Inc.
Epilepsies, Myoclonic, Drug Resistant Epilepsy
 
 
Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Organon
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
TRI-DI-GEP, NCT06267664: Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)

Recruiting
N/A
1500
Europe
Patients with migraine treated with triptans, Lasmiditan or Gepants
Hospital Clínico Universitario de Valladolid
Migraine, Migraine Disorders, Migraine With Aura, Headache Disorders
09/24
12/24
DART, NCT05903040: Ditan Acute tReatments: Effectiveness and Tolerability

Recruiting
N/A
100
Europe
Lasmiditan
University of Florence, IRCCS National Neurological Institute "C. Mondino" Foundation, Società italiana per lo studio delle Cefalee (SISC), Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Azienda Ospedaliero Universitaria Policlinico Modena, Ospedale di Piove di Sacco, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Cliniche Humanitas Gavazzeni, University of Campania "Luigi Vanvitelli", Ospedale di Prato, Azienda Policlinico Umberto I, Auxologico San Luca, Milano, ASST Spedali Civili, Brescia, Carlo Besta Neurological Institute
Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
06/24
06/24
Briumvi (ublituximab-xiiy) / TG Therap
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
ENHANCE, NCT05877963: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Recruiting
3
600
US
Ublituximab, TG-1101, BRIUMVI, Placebo
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
03/26
03/26
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
NCT04130997 / 2019-003625-16: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Active, not recruiting
3
1100
Europe, US, RoW
Ublituximab, TG-1101
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis (RMS)
02/30
02/30
ULTRA-V, NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL

Hourglass Jan 2021 - Mar 2021 : Completion of enrollment in P2 ULTRA-V trial in combination with umbralisib and venetoclax for CLL
Terminated
2/3
277
US
Ublituximab, TG-1101, Umbralisib, TGR-1202, UKONIQ, Venetoclax, Venclexta®
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/22
12/22
NCT04149821: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Terminated
2
1
US
Umbralisib, TGR-1202, Ublituximab, TG-1101
Weill Medical College of Cornell University, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL
01/22
06/22
NCT04783415: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Hourglass Jul 2023 - Dec 2023 : From trial in combination with Utuxin and Ukoniq for 1L MCL
Active, not recruiting
2
12
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
07/22
09/25
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Active, not recruiting
2
29
US
Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603
Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
12/23
01/28
NCT05152459: Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Withdrawn
1/2
48
NA
Tazemetostat, E7438, EPZ-6438, EPZ6438, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
12/24
NCT03804996: Study of TG-1801 in Subjects With B-Cell Lymphoma

Completed
1
50
RoW
TG-1801, Ublituximab, TG-1101, LFB-R603
TG Therapeutics, Inc.
B-Cell Lymphoma
02/24
02/24
TG-1701-101, NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Checkmark From a trial for CLL at EHA 2020
Jun 2020 - Jun 2020: From a trial for CLL at EHA 2020
Terminated
1
172
Europe, RoW
TG-1701, Umbralisib, TGR-1202, Ublituximab, TG-1101
TG Therapeutics, Inc.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/24
05/24
U-PACE, NCT06629428: Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Not yet recruiting
1
25
US
Ublituximab
Georgia State University, Atlanta Neuroscience Institute
Multiple Sclerosis (MS) - Relapsing-remitting
06/26
12/26
NCT04806035: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Terminated
1
21
US
TG-1801, NI-1701, Ublituximab, TG-1101, LFB-R603
TG Therapeutics, Inc.
CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL
06/24
06/24
PROVIDE, NCT06143514: A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Recruiting
N/A
16
US
No intervention
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
06/26
06/26
NCT06433765: A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

Recruiting
N/A
728
US
No intervention
TG Therapeutics, Inc.
Multiple Sclerosis
03/35
03/35
ENABLE, NCT06433752: A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Recruiting
N/A
500
US
No Intervention
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis, Multiple Sclerosis
07/27
07/27
NCT06681623: A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Recruiting
N/A
20
US
Ublituximab
Neurology Center of New England P.C.
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
09/27
09/27
NCT06864936: Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Not yet recruiting
N/A
30
US
Ublituximab, Other disease modifying therapies
University of Maryland, Baltimore, TG Therapeutics, Inc.
Multiple Sclerosis (MS) - Relapsing-remitting
03/27
06/27
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
Besivo (besifovir) / Gilead, LG Chem, Ildong
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT03642340: A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

Recruiting
N/A
3000
RoW
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis b
05/23
08/23
Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
NCT06518577: Immunogenicity of Influenza Vaccinations

Completed
4
605
US
Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland
Influenza
12/24
06/25
DRIVE, NCT04576377: Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

Active, not recruiting
4
977
RoW
FluBlok, Placebo
The University of Hong Kong, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
12/25
12/25
Telotan (rosuvastatin/telmisartan) / Ildong
NCT03648801: A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Not yet recruiting
N/A
600
NA
IlDong Pharmaceutical Co Ltd
Hypertension, Dyslipidemia
05/24
08/24
venadaparib (NOV 1401) / National OncoVenture, Ildong
NCT04725994: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Recruiting
1/2
100
US, RoW
IDX-1197+XELOX, IDX-1197+Irinotecan
Idience Co., Ltd.
Gastric Cancer
09/25
06/26
VASTUS, NCT04174716: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors

Completed
1/2
108
RoW
IDX-1197
Idience Co., Ltd.
Solid Tumors, Homologous Recombination Repair Gene Mutation, Homologous Recombination Deficiency
03/23
06/24
IDG16177 / Evotec, Ildong
NCT04982705: IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Recruiting
1
94
Europe
[Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177, [Part 2] IDG-16177, [Part 1.2] Placebo of IDG-16177, [Part 2] Placebo of IDG-16177
IlDong Pharmaceutical Co Ltd
Type 2 Diabetes
11/22
12/22
temanogrel hydrochloride (APD-791) / Ildong, Pfizer
2020-000238-16: A blinded study to assess the safety, tolerability and effect of Temanogrel on Microvascular Obstruction in subjects undergoing Percutaneous Coronary Intervention (PCI).

Not yet recruiting
2
99
Europe
Temanogrel, APD791, Solution for infusion
Arena Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc.
Microvascular Obstruction, Microvascular Obstruction, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ID119031166 / Ildong
NCT05604287: Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Terminated
1
67
US
ID119031166M, Placebo
IlDong Pharmaceutical Co Ltd, Parexel, YUNOVIA CO.,LTD.
Healthy Participants
04/24
04/24
ID120040002 / Ildong
NCT05663879: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Recruiting
1
86
RoW
ID120040002, Compound-X, Placebo comparator
IlDong Pharmaceutical Co Ltd
Healthy
07/23
07/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belviq (lorcaserin) / Eisai
NCT02400359: Lorcaserin in Obesity: Identification of CNS Targets Using FMRI

Active, not recruiting
4
40
US
Lorcaserin HCl, Belviq, Placebo
Beth Israel Deaconess Medical Center
Obesity, Weight Loss
03/26
03/26
MOMENTUM 1, NCT04572243: A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Terminated
3
28
Canada, US
Placebo, Lorcaserin, E2023
Eisai Inc.
Epilepsies, Myoclonic
08/24
08/24
NCT03266939: Rebalancing the Serotonergic System in Cocaine Dependence

Active, not recruiting
1
10
US
Lorcaserin, Placebo Oral Tablet
Mclean Hospital
Cocaine Dependence
12/21
12/21
NCT04457687: Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Available
N/A
Canada, US
Lorcaserin, E2023
Eisai Inc.
Epilepsies, Myoclonic, Drug Resistant Epilepsy
 
 
Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Organon
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
TRI-DI-GEP, NCT06267664: Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)

Recruiting
N/A
1500
Europe
Patients with migraine treated with triptans, Lasmiditan or Gepants
Hospital Clínico Universitario de Valladolid
Migraine, Migraine Disorders, Migraine With Aura, Headache Disorders
09/24
12/24
DART, NCT05903040: Ditan Acute tReatments: Effectiveness and Tolerability

Recruiting
N/A
100
Europe
Lasmiditan
University of Florence, IRCCS National Neurological Institute "C. Mondino" Foundation, Società italiana per lo studio delle Cefalee (SISC), Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Azienda Ospedaliero Universitaria Policlinico Modena, Ospedale di Piove di Sacco, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Cliniche Humanitas Gavazzeni, University of Campania "Luigi Vanvitelli", Ospedale di Prato, Azienda Policlinico Umberto I, Auxologico San Luca, Milano, ASST Spedali Civili, Brescia, Carlo Besta Neurological Institute
Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
06/24
06/24
Briumvi (ublituximab-xiiy) / TG Therap
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
ENHANCE, NCT05877963: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Recruiting
3
600
US
Ublituximab, TG-1101, BRIUMVI, Placebo
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
03/26
03/26
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
NCT04130997 / 2019-003625-16: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Active, not recruiting
3
1100
Europe, US, RoW
Ublituximab, TG-1101
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis (RMS)
02/30
02/30
ULTRA-V, NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL

Hourglass Jan 2021 - Mar 2021 : Completion of enrollment in P2 ULTRA-V trial in combination with umbralisib and venetoclax for CLL
Terminated
2/3
277
US
Ublituximab, TG-1101, Umbralisib, TGR-1202, UKONIQ, Venetoclax, Venclexta®
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/22
12/22
NCT04149821: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Terminated
2
1
US
Umbralisib, TGR-1202, Ublituximab, TG-1101
Weill Medical College of Cornell University, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL
01/22
06/22
NCT04783415: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Hourglass Jul 2023 - Dec 2023 : From trial in combination with Utuxin and Ukoniq for 1L MCL
Active, not recruiting
2
12
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
07/22
09/25
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Active, not recruiting
2
29
US
Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603
Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
12/23
01/28
NCT05152459: Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Withdrawn
1/2
48
NA
Tazemetostat, E7438, EPZ-6438, EPZ6438, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
12/24
NCT03804996: Study of TG-1801 in Subjects With B-Cell Lymphoma

Completed
1
50
RoW
TG-1801, Ublituximab, TG-1101, LFB-R603
TG Therapeutics, Inc.
B-Cell Lymphoma
02/24
02/24
TG-1701-101, NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Checkmark From a trial for CLL at EHA 2020
Jun 2020 - Jun 2020: From a trial for CLL at EHA 2020
Terminated
1
172
Europe, RoW
TG-1701, Umbralisib, TGR-1202, Ublituximab, TG-1101
TG Therapeutics, Inc.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/24
05/24
U-PACE, NCT06629428: Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Not yet recruiting
1
25
US
Ublituximab
Georgia State University, Atlanta Neuroscience Institute
Multiple Sclerosis (MS) - Relapsing-remitting
06/26
12/26
NCT04806035: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Terminated
1
21
US
TG-1801, NI-1701, Ublituximab, TG-1101, LFB-R603
TG Therapeutics, Inc.
CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL
06/24
06/24
PROVIDE, NCT06143514: A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Recruiting
N/A
16
US
No intervention
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
06/26
06/26
NCT06433765: A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

Recruiting
N/A
728
US
No intervention
TG Therapeutics, Inc.
Multiple Sclerosis
03/35
03/35
ENABLE, NCT06433752: A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Recruiting
N/A
500
US
No Intervention
TG Therapeutics, Inc.
Relapsing Multiple Sclerosis, Multiple Sclerosis
07/27
07/27
NCT06681623: A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Recruiting
N/A
20
US
Ublituximab
Neurology Center of New England P.C.
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
09/27
09/27
NCT06864936: Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Not yet recruiting
N/A
30
US
Ublituximab, Other disease modifying therapies
University of Maryland, Baltimore, TG Therapeutics, Inc.
Multiple Sclerosis (MS) - Relapsing-remitting
03/27
06/27
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
Besivo (besifovir) / Gilead, LG Chem, Ildong
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT03642340: A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

Recruiting
N/A
3000
RoW
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis b
05/23
08/23
Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
NCT06518577: Immunogenicity of Influenza Vaccinations

Completed
4
605
US
Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland
Influenza
12/24
06/25
DRIVE, NCT04576377: Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

Active, not recruiting
4
977
RoW
FluBlok, Placebo
The University of Hong Kong, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
12/25
12/25
Telotan (rosuvastatin/telmisartan) / Ildong
NCT03648801: A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Not yet recruiting
N/A
600
NA
IlDong Pharmaceutical Co Ltd
Hypertension, Dyslipidemia
05/24
08/24
venadaparib (NOV 1401) / National OncoVenture, Ildong
NCT04725994: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Recruiting
1/2
100
US, RoW
IDX-1197+XELOX, IDX-1197+Irinotecan
Idience Co., Ltd.
Gastric Cancer
09/25
06/26
VASTUS, NCT04174716: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors

Completed
1/2
108
RoW
IDX-1197
Idience Co., Ltd.
Solid Tumors, Homologous Recombination Repair Gene Mutation, Homologous Recombination Deficiency
03/23
06/24
IDG16177 / Evotec, Ildong
NCT04982705: IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Recruiting
1
94
Europe
[Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177, [Part 2] IDG-16177, [Part 1.2] Placebo of IDG-16177, [Part 2] Placebo of IDG-16177
IlDong Pharmaceutical Co Ltd
Type 2 Diabetes
11/22
12/22
temanogrel hydrochloride (APD-791) / Ildong, Pfizer
2020-000238-16: A blinded study to assess the safety, tolerability and effect of Temanogrel on Microvascular Obstruction in subjects undergoing Percutaneous Coronary Intervention (PCI).

Not yet recruiting
2
99
Europe
Temanogrel, APD791, Solution for infusion
Arena Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc.
Microvascular Obstruction, Microvascular Obstruction, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ID119031166 / Ildong
NCT05604287: Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Terminated
1
67
US
ID119031166M, Placebo
IlDong Pharmaceutical Co Ltd, Parexel, YUNOVIA CO.,LTD.
Healthy Participants
04/24
04/24
ID120040002 / Ildong
NCT05663879: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Recruiting
1
86
RoW
ID120040002, Compound-X, Placebo comparator
IlDong Pharmaceutical Co Ltd
Healthy
07/23
07/23

Download Options